Skip to main content
Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep

Dr. John Cush RheumNow

1 year 5 months ago
Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep 80mg vs PBO at wk 16 (52% vs 13%; p=0.0006) w/ 40mg=48%. Other arthritis, psoriasis, enthesitis, dactylitis, QOL outcomes also improved.https://t.co/CQn9EVjr9g https://t.co/vVnTo2FPV6
AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in

Dr. John Cush RheumNow

1 year 5 months ago
AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in 5 yrs of Dx best by iCCP3, RFIgA, RFIgM; and 104 proteins differentially expressed & gene analyses showed 21 pathways enriched ≤5 years of Dx. https://t.co/u8abvqNtnX
Daily purposeful walking assoc w/ lower risk of Knee OA (KOA). UK Biobank study of 89,969 persons, F/U 6.8 yrs - 2711 de

Dr. John Cush RheumNow

1 year 5 months ago
Daily purposeful walking assoc w/ lower risk of Knee OA (KOA). UK Biobank study of 89,969 persons, F/U 6.8 yrs - 2711 developed KOA. HRs for incident KOA were 0.84 (0.76-0.92), 0.81 (0.71-0.90), and 0.74 (0.64-0.85) if walking ~5000, ~7000, & ≥8000 steps/d, respectively https://t.co/St9QLuOy9R
Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and

Natasha Salman, DO DrNatashaSalman

1 year 5 months ago
Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and boosts remission rates without background immunosuppressants. CD19+ B-cell depletion shows promise as a new treatment. #Rheum @RheumNow https://t.co/7iSyPfnMV0 https://t.co/M51b0dipMs
Our Chief Medical Editor Leonard H. Calabrese, DO, (@LCalabreseDO) shares his reflections on the book: Masterclass in Me

Healio Rheumatology HealioRheum

1 year 5 months ago
Our Chief Medical Editor Leonard H. Calabrese, DO, (@LCalabreseDO) shares his reflections on the book: Masterclass in Medicine: Lessons from the Experts @ClevelandClinic https://t.co/gZhbrBLcnR
Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M

Dr. John Cush RheumNow

1 year 5 months ago
Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/j8ZWFY4fgx
A large scale genomic population study found antinuclear antibodies (ANA) in up to 14% of the population; most with ANA are asymptomatic, and ANA production is not associated with significant genetic risk. 
A Nature article details the results of an osteoarthritis, genome-wide association study meta-analyses across up to 489,975 cases and 1,472,094 controls, establishing 962 independent associations, 513 of which have not been previously reported. Results were published this week in the journal Nature.
Rheums! Have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast.

Dr. John Cush RheumNow

1 year 5 months ago
Rheums! Have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/uLoRmsAkiG https://t.co/ExthuSBSXs
RheumNow Live 2025 is now available On Demand

For the first time, https://t.co/4UQlqwujiR is offering exclusive access

Dr. John Cush RheumNow

1 year 5 months ago
RheumNow Live 2025 is now available On Demand For the first time, https://t.co/4UQlqwujiR is offering exclusive access to: ✅ 7 STEP Talks from top rheumatology experts ✅ 21 Powerful lectures and Q & A Panels answering real-world questions ✅ All speaker slides and handouts https://t.co/saW9WH4djO
In a murine model of Kawasaki Dz vasculitis- depleting gut microbiota reduces KD like vasculitis. CV lesions were assoc

Dr. John Cush RheumNow

1 year 5 months ago
In a murine model of Kawasaki Dz vasculitis- depleting gut microbiota reduces KD like vasculitis. CV lesions were assoc w/ decrease in Akkermansia muciniphila and Faecalibacterium prausnitzii. Replacement attenuated these findings. https://t.co/Hnij8TWkYy https://t.co/wEuVcuAZ5j
Systematic review of >90 studies on Pregnancy and RA risk indicates that parity, gravidity, infertility, pregnancy lo

Dr. John Cush RheumNow

1 year 5 months ago
Systematic review of >90 studies on Pregnancy and RA risk indicates that parity, gravidity, infertility, pregnancy loss do not adversely affect RA development. But low birthweight was assoc w/ RA Dx/severity, and pre-eclampsia incr risk of subsequent RA Dx. https://t.co/jVa4tmSqvj
Is High Dose Aspirin Needed in Kawasaki Disease (KD)?

Does aspirin add any advantage to intravenous immunoglobulin (IV

Dr. John Cush RheumNow

1 year 5 months ago
Is High Dose Aspirin Needed in Kawasaki Disease (KD)? Does aspirin add any advantage to intravenous immunoglobulin (IVIG) alone in children with KD? A randomized clinical trial IVIG alone was not inferior to IVIG plus aspirin, suggesting that high-dose aspirin during initial https://t.co/vThkP4AH6x
Recent Medscape Physician Compensation Report 2025, MD Salaries dropped by:
Dermatology: -11%
Neurology: -6%
Urology: -6

Dr. John Cush RheumNow

1 year 5 months ago
Recent Medscape Physician Compensation Report 2025, MD Salaries dropped by: Dermatology: -11% Neurology: -6% Urology: -6% Plastic surgery: -4% Cardiology: -4% Ophthalmology: -4% Gastroenterology: -3% Rheumatology: -3% https://t.co/WZDM7XxeEU https://t.co/PhRlHaXsMb
×